Gold bars to be exempt from tariffs, White House clarifies
FRAMINGHAM, MA - Xenetic Biosciences, Inc. (NASDAQ:XBIO), a micro-cap biotech company with a market capitalization of $5.5 million, announced Wednesday it has extended its research collaboration with The Scripps Research Institute to further develop its DNase-based oncology platform in combination with CAR T-cell therapies. According to InvestingPro data, the company has shown strong momentum with positive returns over the past three months.
The expanded program will include additional models of lymphoma and leukemia to validate findings from previous studies. Earlier research conducted at Scripps using lymphoma and metastatic melanoma models demonstrated that co-administration of DNase I with CAR-T cells significantly reduced tumor burden and extended survival compared to CAR-T cell therapy alone. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt on its balance sheet and liquid assets exceeding short-term obligations.
Xenetic’s systemic DNase I candidate, XBIO-015, is designed to degrade neutrophil extracellular traps (NETs), which are weblike structures in the tumor microenvironment that can promote cancer spread and immunosuppression. The company’s research indicates that removing these structures enhances CAR-T cell infiltration into tumors.
"We are pleased to further expand our collaboration with Scripps Research and explore the full potential of our DNase-based oncology platform," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, in the press release statement.
The company is advancing its DNase-based technology toward Phase 1 clinical development for pancreatic carcinoma and other locally advanced or metastatic solid tumors. The platform aims to improve outcomes of existing cancer treatments by targeting NETs involved in cancer progression.
Xenetic Biosciences focuses on developing immuno-oncology technologies for difficult-to-treat cancers. The information in this article is based on a company press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.